238 related articles for article (PubMed ID: 29674128)
21. A prospective study on the role of CXCL13 in Lyme neuroborreliosis.
Schmidt C; Plate A; Angele B; Pfister HW; Wick M; Koedel U; Rupprecht TA
Neurology; 2011 Mar; 76(12):1051-8. PubMed ID: 21422457
[TBL] [Abstract][Full Text] [Related]
22. Sensitivity and specificity of cerebrospinal fluid CXCL13 for diagnosing Lyme neuroborreliosis - a study on 1410 patients and review of the literature.
Lintner H; Hochgatterer-Rechberger P; Pischinger B; Seier J; Vollmann P; Haushofer A; Rittner H; Sommer C; Topakian R
J Neurol Sci; 2020 Jul; 414():116843. PubMed ID: 32344220
[TBL] [Abstract][Full Text] [Related]
23. Cerebrospinal fluid CXCL13 in non-borrelial central nervous system infections: contribution of CXCL13 to the differential diagnosis.
Smíšková D; Džupová O; Moravcová L; Pícha D
Infect Dis (Lond); 2023 Aug; 55(8):551-558. PubMed ID: 37317698
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic performance of cerebrospinal fluid free light chains in Lyme neuroborreliosis - a pilot study.
Tjernberg I; Johansson M; Henningsson AJ
Clin Chem Lab Med; 2019 Nov; 57(12):2008-2018. PubMed ID: 31199760
[TBL] [Abstract][Full Text] [Related]
25. The chemokine CXCL13 in acute neuroborreliosis.
Senel M; Rupprecht TA; Tumani H; Pfister HW; Ludolph AC; Brettschneider J
J Neurol Neurosurg Psychiatry; 2010 Aug; 81(8):929-33. PubMed ID: 19965843
[TBL] [Abstract][Full Text] [Related]
26. Laboratory diagnosis of Lyme neuroborreliosis is influenced by the test used: comparison of two ELISAs, immunoblot and CXCL13 testing.
Wutte N; Archelos J; Crowe BA; Zenz W; Daghofer E; Fazekas F; Aberer E
J Neurol Sci; 2014 Dec; 347(1-2):96-103. PubMed ID: 25288328
[TBL] [Abstract][Full Text] [Related]
27. High sensitivity and specificity of the C6-peptide ELISA on cerebrospinal fluid in Lyme neuroborreliosis patients.
van Burgel ND; Brandenburg A; Gerritsen HJ; Kroes AC; van Dam AP
Clin Microbiol Infect; 2011 Oct; 17(10):1495-500. PubMed ID: 21375653
[TBL] [Abstract][Full Text] [Related]
28. Prospective study on the chemokine CXCL13 in neuroborreliosis and other aseptic neuroinfections.
Pícha D; Moravcová L; Smíšková D
J Neurol Sci; 2016 Sep; 368():214-20. PubMed ID: 27538636
[TBL] [Abstract][Full Text] [Related]
29. Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid.
van Burgel ND; Bakels F; Kroes AC; van Dam AP
J Clin Microbiol; 2011 May; 49(5):2027-30. PubMed ID: 21367992
[TBL] [Abstract][Full Text] [Related]
30. Specificity and Diagnostic Utility of Cerebrospinal Fluid CXCL13 in Lyme Neuroborreliosis.
Eckman EA; Clausen DM; Herdt AR; Pacheco-Quinto J; Halperin JJ
Clin Infect Dis; 2021 May; 72(10):1719-1726. PubMed ID: 32221538
[TBL] [Abstract][Full Text] [Related]
31. The potential for CXCL13 in CSF as a differential diagnostic tool in central nervous system infection.
Masouris I; Klein M; Ködel U
Expert Rev Anti Infect Ther; 2020 Sep; 18(9):875-885. PubMed ID: 32479125
[No Abstract] [Full Text] [Related]
32. Cerebrospinal fluid chemokine CXCL13 in the diagnosis of neuroborreliosis in children.
Sillanpää H; Skogman BH; Sarvas H; Seppälä IJ; Lahdenne P
Scand J Infect Dis; 2013 Jul; 45(7):526-30. PubMed ID: 23521134
[TBL] [Abstract][Full Text] [Related]
33. Point-of-care testing for CXCL13 in Lyme neuroborreliosis.
Pietikäinen A; Oksi J; Hytönen J
Diagn Microbiol Infect Dis; 2018 Jul; 91(3):226-228. PubMed ID: 29567125
[TBL] [Abstract][Full Text] [Related]
34. The chemokine CXCL13 is elevated in the cerebrospinal fluid of patients with neurosyphilis.
Dersch R; Hottenrott T; Senel M; Lehmensiek V; Tumani H; Rauer S; Stich O
Fluids Barriers CNS; 2015 May; 12():12. PubMed ID: 25975424
[TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid levels of the macrophage-specific biomarker sCD163 are diagnostic for Lyme neuroborreliosis: An observational cohort study.
Ørbæk M; Gynthersen RMM; Mens H; Brandt C; Stenør C; Wiese L; Andersen ÅB; Møller HJ; Lebech AM
Clin Chim Acta; 2023 Mar; 543():117299. PubMed ID: 36931585
[TBL] [Abstract][Full Text] [Related]
36. Chemokine CXCL13 concentration in cerebrospinal fluid in patients with neuroborreliosis--own observations.
Kępa L; Oczko-Grzesik B; Sobala-Szczygieł B; Boroń-Kaczmarska A
Przegl Epidemiol; 2015; 69(4):705-10, 851-5. PubMed ID: 27139348
[TBL] [Abstract][Full Text] [Related]
37. Neuroborreliosis and acute encephalopathy: The use of CXCL13 as a biomarker in CNS manifestations of Lyme borreliosis.
Karrasch M; Fingerle V; Boden K; Darr A; Baier M; Straube E; Nenadic I
Ticks Tick Borne Dis; 2018 Feb; 9(2):415-417. PubMed ID: 29246814
[TBL] [Abstract][Full Text] [Related]
38. CXCL13 may improve diagnosis in early neuroborreliosis with atypical laboratory findings.
Borde JP; Meier S; Fingerle V; Klier C; Hübner J; Kern WV
BMC Infect Dis; 2012 Dec; 12():344. PubMed ID: 23228054
[TBL] [Abstract][Full Text] [Related]
39. The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis.
Rupprecht TA; Plate A; Adam M; Wick M; Kastenbauer S; Schmidt C; Klein M; Pfister HW; Koedel U
J Neuroinflammation; 2009 Dec; 6():42. PubMed ID: 20042073
[TBL] [Abstract][Full Text] [Related]
40. CXCL13 as a diagnostic marker of neuroborreliosis and other neuroinflammatory disorders in an unselected group of patients.
Wagner JN; Weis S; Kubasta C; Panholzer J; von Oertzen TJ
J Neurol; 2018 Jan; 265(1):74-81. PubMed ID: 29134272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
